<DOC>
	<DOC>NCT01458041</DOC>
	<brief_summary>Monitoring efficacy and safety aspects of iv. iloprost therapy of patients with critical limb ischemia by recording clinical parameters.</brief_summary>
	<brief_title>Iloprost Therapy in Patients With Critical Limb Ischemia</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Patients who fulfill the internationally defined criteria of critical limb ischemia; Patients who are not eligible for vascular surgery or angioplasty interventions and Patients who are treated with iloprost infusion. The treating physician has decided iloprost treatment before study enrollment. Exclusion criteria are in accordance with the Summary of Product Characteristics of Ilomedin.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Critical limb ischaemia</keyword>
	<keyword>Iloprost</keyword>
	<keyword>Quality of life</keyword>
	<keyword>Visual analogue scale</keyword>
</DOC>